Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$BNTX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$3.24 down -102.50% YoY • Reported revenue of $145.8M down -44.10% YoY • BioNTech is revising its full-year 2026 revenue guidance to 1.61.9 billion, while maintaining adjusted SG&A expenses at 700800 million and adjusting R&D expense guidance to 2.02.3 billion for BioNTech.
1

Price since post

Full Details
AdibRamadan
This is not expected, but rather well-known: the company's policy is to lull investors into complacency, hoping for a longer period of profitability or a strong resurgence of COVID-19. The mRNA platform, over the course of 30 years, has made no progress in cancer treatments.

Advertisement|Remove ads.